# CyclASol® Phase 1 Study

> **NCT02113293** · PHASE1 · COMPLETED · sponsor: **Novaliq GmbH** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** CyclASol®
- **DRUG:** Placebo (vehicle)

## Key facts

- **NCT ID:** NCT02113293
- **Lead sponsor:** Novaliq GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2014-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02113293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02113293, "CyclASol® Phase 1 Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02113293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*